Opioid-Free Medication Regimen for Pain Control for Patients Undergoing Robot Assisted Radical Prostatectomy for Prostate Cancer

Inclusion Criteria

• All men ages 40-75 undergoing robot assisted radical prostatectomy (RARP) with or without bilateral lymph node dissection with low, intermediate, or high-risk prostate cancer.
• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal.
• Creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
• Ability to understand and the willingness to sign an institutional review board (IRB)-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria

• Participants with known allergies to any medication involved in the study or its excipients.
• Participants who are incarcerated persons.
• Participants with a chronic narcotic dependence.
• Participants with any prescription for narcotics in the past 30 days.
• Participants who have had only major pelvic or abdominal surgeries such as bowel, rectal colon, bladder, liver, gall bladder, kidney etc. in the past 6 months.
• Patients may not be receiving any other investigational agents.
• Patients with known metastatic disease or brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.